Table 2—

Prevalence (%) of MetS and its components in the glucose tolerance study subgroup (n = 2,049) of the FINRISK cohort by sex and age-group

Men
PWomen
PP between sexes
45–54 years55–64 years45–54 years55–64 years
n427509535578
MetS36.241.40.11616.527.9<0.001<0.001
NGT with insulin resistance12.29.50.19415.115.00.977<0.004
IFG14.512.40.3375.83.60.089<0.001
IGT8.913.80.0216.912.60.0010.226
Diabetes7.512.60.1045.28.30.0420.005
Obesity77.681.90.10426.939.4<0.001<0.001
BMI >30 kg/m226.526.50.98419.629.4<0.0010.355
Abdominal obesity76.980.90.13418.325.10.006<0.001
Hypertension60.771.5<0.00143.266.5<0.001<0.001
Systolic blood pressure ≥140 mmHg46.662.3<0.00134.059.5<0.001<0.001
Diastolic blood pressure ≥90 mmHg44.342.10.45924.926.50.539<0.001
Use of antihypertensive medication15.020.60.01011.021.1<0.0010.225
Dyslipidemia51.753.00.71221.136.8<0.001<0.001
Low HDL cholesterol (men <0.9 women <1.0 mmol/l)9.414.00.0294.76.40.229<0.001
Triglycerides ≥1.7 (mmol/l)44.745.60.79915.729.6<0.001<0.001
Use of lipid-lowering medication3.55.00.2850.94.00.0040.046
  • Obesity: BMI >30 kg/m2 or WHR >0.9 in men and >0.85 in women. Abdominal obesity: WHR >0.9 in men and >0.85 in women. Hypertension: systolic ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive medication. Dyslipidemia: triglycerides ≥1.7 mmol/l or HDL cholesterol <0.9 in men and <1.0 mmol/l in women or use of lipid-lowering medication.